2025-06-03T09:56:20-04:00 2024-12-31 873924813 ADD ACCOUNTING INC 7 W MAIN ST SHIREMANSTOWN PA 17011 990 2024-01-01 251857128 CENTRAL PA TRANSPLANT FOUNDATN INC CENT 7172318804 205 S FRONT ST 8TH FL BRADY BLDG HARRISBURG PA 17104 HAROLD C YANG MD PRESIDENT 7172318400 2025-05-09 true ANDREW DONNELLY P01570402 7177636890 2025-05-09 2024 2025-03-06 01:10:19Z HAROLD C YANG MD 112353 false X N/A X TO PROMOTE AND FOSTER ADVANCES IN TRANSPLANTATION THRU ACTIVITIES THAT HAVE INCLUDED PARTICIPATION IN CLINICAL TRIALS INVESTIGATING DIFFERENT IMMUNOSUPPRESSIVE REGIMENS, DEVELOPMENT OF CLINICAL PATHWAYS TO ENHANCE PATIENT CARE, FORUMS FOR PUBLIC AND PHYSICIAN EDUCATION IN TRANSPLANTA- TION, STUDIES RELATED TO OUTCOMES RESEARCH, LABORATORY WORK IN IMMUNOBIOLOGY AND NEW CONCEPTS IN DIABETES MANAGEMENT. 3 2 0 0 0 20732 10282 97508 85310 0 118240 95592 0 0 0 0 0 126281 94443 126281 94443 -8041 1149 40954 55219 13116 40954 42103 X TO PROMOTE AND FOSTER ADVANCES IN TRANSPLANTATION THRU ACTIVITIES THAT HAVE INCLUDED PARTICIPATION IN CLINICAL TRIALS INVESTIGATING DIFFERENT IMMUNOSUPPRESSIVE REGIMENS, DEVELOPMENT OF CLINICAL PATHWAYS TO ENHANCE PATIENT CARE, FORUMS FOR PUBLIC AND PHYSICIAN EDUCATION IN TRANSPLANTA- TION, STUDIES RELATED TO OUTCOMES RESEARCH, LABORATORY WORK IN IMMUNOBIOLOGY AND NEW CONCEPTS IN DIABETES MANAGEMENT. false false 46188 10282 1. VITAERIS PROTOCOL VKTX01 "A PIVOTAL PHASE 3 TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF CLAZAKIZUMAB FOR THE TREATMENT OF CHRONIC ACTIVE-MEDICATED REJECTION IN KIDNEY TRANSPLANT RECIPIENTS". APRIL 2019-DECEMBER 2024. 2. APOL 1 LONG-TERM KIDNEY TRANSPLANTATION OUTCOMES NETWORK PROTOCOL SUMMARY FOR NON-ENGAGED SITES (APOLLO) NIH SPONSORED. MARCH 2020-PRESENT. 3. NATERA PROTOCOL 20-048-TRP "RENASIGHT CLINICAL APPLICATION, REVIEW, AND EVALUATION (RENACARE) STUDY DECEMBER 2021-JULY 2024. 4. ELEDON BESTOW PROTOCOL AT-1501-K207 "A PHASE 2, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TEGOPRUBART IN PATIENTS UNDERGOING KIDNEY TRANSPLANTATION" AUGUST 2023-PRESENT (ACTIVE). 8430 DEPRECIATION ON ASSETS USED IN RESEARCH. 8430 54618 true false false false false false false false false false true false false true true false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false true 1 0 true 0 false false false false false false false false false false false false false false false false false X 3 2 false false false false false false false true true false false true false false false false false false PA X HARRY C YANG MD 7172318804 205 S FRONT ST BRADY 8 HARRISBURG PA 17104 X JONATHAN R DIAMOND DIRECTOR X 0 0 0 HAROLD C YANG MD PRESIDENT X X 0 0 0 MARY M WAYBILL PHYSICIAN X 0 0 0 false false false TRANPLANTATION RESEARCH 10282 10282 10282 72 72 101999 16761 85238 85238 85238 95592 85310 10282 550 550 4832 4832 8430 8430 MEDICAL PROFESSIONALS 40984 40984 OFFICE EXPENSE 13872 13872 MEALS & ENTERTAINMENT 11617 11617 GIFTS/PROMOTION 7005 7005 7153 372 6781 94443 54618 39825 0 4253 46611 27312 27729 19299 8972 27470 8450 40954 55219 13116 0 13116 X 40954 42103 40954 42103 40954 55219 1149 X false false X 15174 30720 29169 20732 10282 106077 15174 30720 29169 20732 10282 106077 106077 613 34 241 277 72 1237 5373 10282 15655 122969 1237 0.86260 0.78140 X PART II, LINE 10 OTHER INCOME 5,373 27312 -27312 46611 46611 19299 OTHER ASSETS 8450 8450 CASH OVERDRAFT 13116 13116 FORM 990 - ORGANIZATION'S MISSION TO PROMOTE AND FOSTER ADVANCES IN TRANSPLANTATION THRU ACTIVITIES THAT HAVE INCLUDED PARTICIPATION IN CLINICAL TRIALS INVESTIGATING DIFFERENT IMMUNOSUPPRESSIVE REGIMENS, DEVELOPMENT OF CLINICAL PATHWAYS TO ENHANCE PATIENT CARE, FORUMS FOR PUBLIC AND PHYSICIAN EDUCATION IN TRANSPLANTA- TION, STUDIES RELATED TO OUTCOMES RESEARCH, LABORATORY WORK IN IMMUNOBIOLOGY AND NEW CONCEPTS IN DIABETES MANAGEMENT. FORM 990, PAGE 2, PART III, LINE 4D DEPRECIATION ON ASSETS USED IN RESEARCH. FORM 990, PAGE 6, PART VI, LINE 11B APPROVED BY TREASURER BEFORE SUBMISSION. FORM 990, PAGE 6, PART VI, LINE 19 UPON REQUEST.